Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, controlled trial (ESTEEM 1)

Plaque Psoriasis ◽

Controlled Trial ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Faculty Opinions recommendation of Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725781037.793521633 ◽

2016 ◽

Author(s):

Gil Yosipovitch ◽

Leigh Nattkemper

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial

The Journal of Dermatology ◽

10.1111/1346-8138.13829 ◽

2017 ◽

Vol 44 (8) ◽

pp. 873-884 ◽

Cited By ~ 19

Author(s):

Mamitaro Ohtsuki ◽

Yukari Okubo ◽

Mayumi Komine ◽

Shinichi Imafuku ◽

Robert M. Day ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Japanese Patients ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0392 Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of A Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2014-eular.4419 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 736.1-736 ◽

Author(s):

F. Zhang ◽

T. Tencer ◽

S. Li

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Work Productivity ◽

Phase 3 ◽

Productivity Improvement ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

10.1136/annrheumdis-2013-eular.526 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A163-A163 ◽

Cited By ~ 5

Author(s):

A. Kavanaugh ◽

P. J. Mease ◽

A. O. Adebajo ◽

J. Wollenhaupt ◽

C. Hu ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0402 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of A Phase 3, Randomized, Controlled Trial (PALACE 1)

10.1136/annrheumdis-2014-eular.3878 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 739.4-740 ◽

Author(s):

P. Schafer ◽

P. Chen ◽

L. Fang ◽

A. Wang ◽

R. Chopra

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2014-eular.1575 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 730.2-730 ◽

Author(s):

A. Adebajo ◽

A. Wells ◽

C. Edwards ◽

A. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Efficacy and safety of apremilast with or without topical or phototherapy: Subanalysis of the population with < PASI-75 in the ESTEEM 1 phase 3, randomized, controlled trial in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.963 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB246 ◽

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Randomized Controlled

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.682 ◽

2014 ◽

Vol 70 (5) ◽

pp. AB164 ◽

Keyword(s):

Controlled Trial ◽

Severe Psoriasis ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

214. Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis and Current Skin Involvement: Results of Palace 3, a Phase 3, Randomized, Controlled Trial

Rheumatology ◽

10.1093/rheumatology/keu115.008 ◽

2014 ◽

Vol 53 (suppl_1) ◽

pp. i139-i140 ◽

Cited By ~ 2

Author(s):

Christopher J. Edwards ◽

Francisco J. Blanco ◽

Jeffrey Crowley ◽

ChiaChi Hu ◽

Randall M. Stevens ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Physical Function ◽

Controlled Trial ◽

Skin Involvement ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽